文献速递炎症性肠病

皮下英夫利昔单抗单药治疗与联合治疗在炎症性肠病中的免疫原性和疗效:系统评价与荟萃分析

Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-05-14

该系统评价与荟萃分析纳入24项研究共3172例炎症性肠病患者,评估皮下英夫利昔单抗单药与联合治疗的免疫原性和疗效。从静脉诱导转为皮下注射的患者中,单药治疗抗药抗体阳性率中位数68% vs 联合治疗48%(OR 3.29,95%CI 1.71-6.31,P<.001)。12个月临床应答率相当,联合治疗有趋势但未达统计学显著(OR 0.73,95%CI 0.50-1.06,P=.10)。

要点

  • 从静脉诱导转皮下英夫利昔单抗者,单药治疗免疫原性高于联合治疗(中位数68% vs 48%)
  • 12个月临床应答率两组相当,联合治疗有趋势但未达统计学显著(OR 0.73,P=.10)
  • 从静脉维持转皮下者复发率低(6个月中位数12%,第50周11%),治疗持续率高(6个月93%,12个月92%)

核心结论

  • 皮下英夫利昔单抗单药治疗较联合治疗免疫原性更高,尤其在新开始英夫利昔单抗治疗的患者中。
  • 临床应答率相当,但联合治疗有趋势,需进一步研究。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2024年8月,纳入24项研究共3172例接受皮下英夫利昔单抗治疗的炎症性肠病患者。
  • 主要结局为开始皮下英夫利昔单抗后或从静脉转为皮下后12个月内抗药抗体形成。
  • 次要结局包括治疗持续率、临床疗效和生化指标。

主要发现

  • 从静脉英夫利昔单抗诱导转为皮下注射的患者中,单药治疗免疫原性更常见(中位数68% vs 48%;OR 3.29;95%CI 1.71-6.31;P<.001)。
  • 12个月临床应答率两组相当,联合治疗有趋势(OR 0.73;95%CI 0.50-1.06;P=.10)。
  • 从静脉维持治疗转为皮下英夫利昔单抗的患者中,复发率低(6个月中位数12%,第50周11%),生化标志物稳定。
  • 治疗持续率高(6个月93%,12个月92%)。
  • 转换时疾病静止的患者1年复发率为9%至11%,基线免疫原性预测治疗失败。

临床怎么用

  • 作者认为皮下英夫利昔单抗单药治疗较联合治疗免疫原性更高,尤其在新开始英夫利昔单抗治疗的患者中。
  • 作者指出临床应答率相当,但联合治疗有趋势,需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Intravenous (IV) infliximab (IFX) combined with an immunomodulator (combination therapy) outperforms IV IFX monotherapy in terms of clinical, endoscopic, and immunogenicity outcomes in patients with inflammatory bowel disease (IBD). With the advent of subcutaneous (SC) IFX, which is associated with higher serum drug concentrations, it is essential to assess whether SC IFX monotherapy provides similar pharmacokinetic and clinical benefits as combination therapy. METHODS: We conducted a systematic review and meta-analysis (until August 2024), of studies on patients with IBD treated with SC IFX. The primary outcome was anti-drug antibodies (ADAs) formation within 12 months (M) after starting SC IFX or after switching from IV to SC IFX. Secondary outcomes included treatment persistence, clinical efficacy, and biochemical parameters. RESULTS: Twenty-four studies (N = 3172) were included. Among patients transitioning from IV IFX induction to SC IFX, immunogenicity was more prevalent with monotherapy than combination treatment (median, 68% vs 48%; odds ratio [OR], 3.29; 95% confidence interval [CI], 1.71-6.31; P < .001). Clinical response rates at 12M were comparable, with a trend favoring combination therapy (OR, 0.73; 95% CI, 0.50-1.06; P = .10). In patients switching from IV maintenance to SC IFX, relapse rates were low (median, 12% at 6M, 11% at week 50), with stable biochemical markers. Treatment persistence was high (93% at 6M, 92% at 12M). Among patients with quiescent disease at the time of switching, 1-year relapse rates were 9% to 11%, with baseline immunogenicity predicting treatment failure. CONCLUSIONS: SC IFX monotherapy is associated with higher immunogenicity rates compared with combination therapy, particularly in new IFX starters. Although clinical response was comparable, a trend favoring combination therapy warrants further investigation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Anjie SI, Gecse KB, Meloni CM, et al. Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40378993. doi:10.1016/j.cgh.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。